AsiaTechDaily – Asia's Leading Tech and Startup Media Platform

  • Topics
    • AI & Big Data
    • AR & VR
    • Blockchain
    • Clean Technology
    • Content & Games
    • Cybersecurity
    • Enterprise & SaaS
    • Gadgets & Electronics
    • Health & Bio
    • FinTech
    • IoT
    • Transportation & Logistics
    • Marketplaces & E-commerce
    • Ecosystem
    • Robotics
    • Investments
    • Events
    • Innovasion Exchange Programme
    • Startup Program
    • EdTech
    • Featured
  • Deals
    • Private Equity
    • Venture Capital
    • IPO & Markets
  • Interviews
    • Investors’ interviews
    • Founders’ interviews
    • Unicorn interview
  • Governments
  • Events
  • Lists
  • Subscription Plan
  • Login
Menu
  • Topics
    • AI & Big Data
    • AR & VR
    • Blockchain
    • Clean Technology
    • Content & Games
    • Cybersecurity
    • Enterprise & SaaS
    • Gadgets & Electronics
    • Health & Bio
    • FinTech
    • IoT
    • Transportation & Logistics
    • Marketplaces & E-commerce
    • Ecosystem
    • Robotics
    • Investments
    • Events
    • Innovasion Exchange Programme
    • Startup Program
    • EdTech
    • Featured
  • Deals
    • Private Equity
    • Venture Capital
    • IPO & Markets
  • Interviews
    • Investors’ interviews
    • Founders’ interviews
    • Unicorn interview
  • Governments
  • Events
  • Lists
  • Subscription Plan
  • Login
Submit Article
Menu
  • Topics
    • AI & Big Data
    • AR & VR
    • Blockchain
    • Clean Technology
    • Content & Games
    • Cybersecurity
    • Enterprise & SaaS
    • Gadgets & Electronics
    • Health & Bio
    • FinTech
    • IoT
    • Transportation & Logistics
    • Marketplaces & E-commerce
    • Ecosystem
    • Robotics
    • Investments
    • Events
    • Innovasion Exchange Programme
    • Startup Program
    • EdTech
    • Featured
  • Deals
    • Private Equity
    • Venture Capital
    • IPO & Markets
  • Interviews
    • Investors’ interviews
    • Founders’ interviews
    • Unicorn interview
  • Governments
  • Events
  • Lists
  • Subscription Plan
  • Login
Submit Article
Join Chat 💬
Private Equity5 Sep 2019 8:08

Hong Kong PE Firm PAG Pays $540m for Majority Stake in Hisun BioRay

by AsiaTechDaily Writer
  • twitter
Bookmark (0)
Please login to bookmark Close

No account yet? Register

Hong Kong-headquartered private equity firm PAG is paying about Rmb3.8 billion (US$540 million) for a controlling stake in Chinese biopharma company Hisun BioRay, according to a company statement.

The Asia-focused PAG will acquire 58 percent in Hisun BioRay, the R&D and manufacturing platform of Shanghai-listed pharmaceutical giant Zhejiang Hisun Pharmaceutical, in what is considered as one of the biggest deals in the country’s biotechnology industry so far.

Hisun Pharmaceutical will continue to retain 42 percent ownership of the company while Xiao Suining, partner and chairman of PAG China, will come in as the new chairman of Hisun BioRay.

Established in January 2019, Hisun BioRay serves as the core business division of Hisun Pharmaceutical. With two R&D and manufacturing centers in Taizhou and Hangzhou, the firm also serves as platform for R&D, manufacturing, sales of Hisun’s biologic anti-body based drugs.

In a statement, Hisun BioRay said it has developed a strong portfolio in the auto-immune and oncology treatment areas. It manufactures and markets Anbainuo®, a leading biosimilar drug indicated for auto-immune disorder including rheumatoid arthritis, ankylosing spondylitis, and psoriasis.

Before the end of this year, the pharma firm, which has more than 700 employees, plans to launch Anjianning®, one of China’s first adalimumab biosimilars.

Hisun BioRay CEO Dr. Wang Haibin said the investment from PAG will help the pharma firm in accelerating the development of its pipeline and clinical trial progress. It will also strengthen the company’s competitive advantage and positions it further as leader in the latest generation of innovative biologics and biosimilars.

For Kevin Xu, head of PAG Growth Capital, the investment in Hisun BioRay further underscores PAG’s strong commitment to China’s biotech industry. The private equity firm recently invested in other biotech firms in China, including Alphamab Oncology and Rongchant Pharmaceuticals.

Hisun Pharmaceutical, the seller of the stake, is listed on the Shanghai Stock Exchange and is headquartered in Taizhou, Zhejiang province.

Tags: BiopharmaHisun BioRayPAGPrivate Equity

Similar Articles

Venture Capital27 Aug 2025 5:10

Rachel Lau’s Iris Capital to Raise $200M for Private Credit and Equity Expansion

More
Private Equity20 Dec 2023 12:58

Singapore’s Novo Tellus PE Fund 3 Closes at $510M, Exceeding Expectations

More
Private Equity17 Aug 2023 6:57

HealthXCapital Merges with Jungle Ventures to Drive Healthcare Expansion

More

Topics

Menu
  • AI & Big Data
  • AR & VR
  • Blockchain
  • Clean Technology
  • Content & Games
  • Cybersecurity
  • Enterprise & SaaS
  • Gadgets & Electronics
  • Health & Bio

Program

Menu
  • Ecosystem
  • EdTech
  • Featured
  • FinTech
  • Investments
  • IoT
  • Marketplaces & E-commerce
  • Robotics
  • Transportation & Logistics

About

Menu
  • Home
  • About us
  • Privacy Policy
  • Collaborate with AsiaTechDaily
Facebook Instagram Linkedin
  • twitter

Subscribe and be informed first hand about the actual economic news.

All the day’s headlines and highlights, direct to you every morning.

© 2023 asiatechdaily. All rights reserved.